Ophthalmology in Georgia

Xstrahl is a global medical device manufacturer specializing in superficial and orthovoltage X-ray radiation therapy systems for clinical and preclinical research applications. The company delivers non-invasive radiation therapy equipment designed to treat non-melanoma skin cancers (basal cell and squamous cell carcinoma), benign dermatological conditions (keloid scarring, Dupuytren's contracture, Ledderhose disease), and palliative care indications. Xstrahl's clinical product line includes the Xstrahl 100, 150, 200, and 300 systems, along with the newer Radiant Aura platform with XBeam treatment planning software. These devices enable office-based and clinic-based treatment delivery by radiation oncologists and dermatologists with treatment outcomes comparable to surgical alternatives. The company also offers radiation research systems for translational research, enabling life science investigators, radiation physicists, and clinicians to conduct clinically relevant experiments. Xstrahl operates globally with North American headquarters in Suwanee, Georgia, and regional operations in the UK and Germany. The systems feature water-cooling technology, multiple energy levels (superficial and intermediate energies), user-friendly interfaces, and high reliability. Xstrahl supports the clinical and research community through educational resources, case studies, publications, presentations, and technical support services. The company positions itself as a leader in expanding access to non-invasive radiation therapy and advancing new treatment applications beyond traditional oncology.

Sutter Medical Technologies USA is a subsidiary of Sutter Medizintechnik GmbH (Germany), a family-owned manufacturer of precision electrosurgical devices founded in 1970. The US operation, based in Alpharetta, Georgia, distributes advanced surgical instruments and radiofrequency generators for ENT, neurosurgery, and dermatological surgery specialties. Core product lines include the CURIS® 4 MHz radiofrequency generator (impedance-controlled electrosurgery for cutting and coagulation), Calvian endo-pen® bipolar forceps (endonasal and transnasal endoscopic surgery), and SuperGliss® non-stick bipolar forceps for microsurgery. The company is the exclusive US distributor of Clearmind Biomedical's Neuroblade System (FDA-cleared multifunctional neuroendoscope for minimally invasive neurosurgery) and the LARS Retractor 2.0 by Fentex Medical (modular laryngeal retractor for transoral robotic surgery and ENT procedures). Additional products include the CURIS® flow irrigation pump. Sutter emphasizes precision, quality, and non-stick technology to reduce char buildup and improve surgical field clarity. The parent company operates ~200 employees across 96,875 sq ft of manufacturing facilities in Germany with certifications supporting distribution in North America and Asia. Products are marketed toward hospital ORs, ASCs, and specialty surgical teams performing precision procedures in cranial base, laryngeal, and endoscopic surgeries.

Clearside Biomedical is a biopharmaceutical company specializing in suprachoroidal drug delivery for sight-threatening diseases of the back of the eye. The company's proprietary SCS® Microinjector® platform enables targeted, in-office suprachoroidal injections that deliver therapeutics to the macula, retina, and choroid with enhanced precision. Clearside has performed over 10,000 clinical injections, establishing deep expertise in commercial execution, clinical development, and regulatory pathways for ocular therapies. XIPERE® (triamcinolone acetonide injectable suspension), approved by the FDA in October 2021, is the first and only FDA-approved suprachoroidal delivery product, indicated for macular edema associated with uveitis. The company is advancing CLS-AX, a small-molecule tyrosine kinase inhibitor candidate in Phase 3 trials targeting the multi-billion dollar wet age-related macular degeneration (wet AMD) market. Clinical programs span six retinal diseases including diabetic macular edema, retinal vein occlusion, and uveitis-related conditions. Clearside partners with pharmaceutical collaborators to expand therapeutic applications of its validated delivery platform.

Atlanta Healthcare Services, Inc., operating under the OcuDrape brand, is a manufacturer of ophthalmic surgical disposables with over 40 years of experience in design, manufacturing, and sales. The company specializes in an extensive line of surgical drapes, fluid control products, equipment covers, and low-lint towels designed specifically for advanced ophthalmic and oculoplastic surgical procedures. OcuDrape products are engineered to provide maximum protection against fluid strike-through, maintain sterile field integrity, and reduce risk of exposure to infectious body fluids. All drapes meet rigorous ANSI/AAMI PB70 Standard for Level 3 device protection through comprehensive testing and quality control processes. Product lines include mini drapes, mid-size drapes, 3/4 body drapes, specialty drapes for various surgical techniques, and lint-free fluid control products. Materials range from embossed plastic and clear plastic to SMS non-woven fabrics, with formulations balancing strength against punctures and abrasions while maintaining flexibility for natural draping and patient comfort. The company serves ophthalmic surgery centers, hospitals, clinics, private practices, ambulatory surgery centers (ASCs), and distributors/resellers. OcuDrape products are suitable for inclusion in custom ophthalmic procedural packs and for direct purchase by healthcare institutions.